{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:22Z","timestamp":1793293882224,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Chiba University Hospital","id":[{"id":"https:\/\/ror.org\/0126xah18","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1136\/ard-2023-224343","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T13:20:16Z","timestamp":1695302416000},"page":"96-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct02198248","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02198248","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02198248","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-2685","authenticated-orcid":false,"given":"Shunsuke","family":"Furuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-9799","authenticated-orcid":false,"given":"Daiki","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-937X","authenticated-orcid":false,"given":"Yoshihisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4682-6268","authenticated-orcid":false,"given":"Masaki","family":"Hiraguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-4528","authenticated-orcid":false,"given":"Takeshi","family":"Umibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kurasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Ninagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Hiromura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9439-8918","authenticated-orcid":false,"given":"Shin-ichiro","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-9381","authenticated-orcid":false,"given":"Hiroshi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224343_bib1","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224343_bib2","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","author":"Ntatsaki","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224343_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2018.1500437","article-title":"Clinical practice guidelines of the Japan research committee of the Ministry of health, labour, and welfare for intractable vasculitis for the management of ANCA-associated vasculitis","volume":"29","author":"Harigai","year":"2019","journal-title":"Modern Rheumatology"},{"key":"10.1136\/ard-2023-224343_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0463.2009.02470.x","article-title":"Treatment of ANCA-associated systemic small-vessel vasculitis","volume":"117","author":"Jayne","year":"2009","journal-title":"APMIS Suppl"},{"key":"10.1136\/ard-2023-224343_bib5","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224343_bib6","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jama.2021.13879","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to Rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial","volume":"326","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2023-224343_bib7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224343_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis. reply","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224343_bib9","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2023-224343_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3899\/jrheum.110705","article-title":"Risk factors associated with relapse in Japanese patients with microscopic Polyangitis","volume":"39","author":"Wada","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224343_bib11","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody Vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or Proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224343_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-224343_bib13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1136\/ard-2023-224343_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic Vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl","key":"10.1136\/ard-2023-224343_bib16","first-page":"MS253","article-title":"The validity and relative precision of MOS Short- and long-form health status scales and Dartmouth COOP charts: results from the medical outcomes study","volume":"30","author":"McHorney","year":"1992","journal-title":"Med Care"},{"key":"10.1136\/ard-2023-224343_bib17","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","article-title":"Translation, adaptation, and validation of the SF-36 health survey for use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/ard-2023-224343_bib18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard-2023-224343_bib19","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224343_bib20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule Rituximab regimen to maintain ANCA-associated vasculitis remission","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224343_bib21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7326\/L20-1199","article-title":"Long-term Rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-224343_bib22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomized controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224343_bib23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3899\/jrheum.160005","article-title":"Comparison of the phenotype and outcome of granulomatosis with polyangiitis between UK and Japanese cohorts","volume":"44","author":"Furuta","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224343_bib24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3899\/jrheum.130602","article-title":"Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan","volume":"41","author":"Furuta","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-224343_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0123-2021","article-title":"Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1136\/ard-2023-224343_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199659","article-title":"Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial Pneumonias","volume":"13","author":"Hozumi","year":"2018","journal-title":"PLoS One"},{"key":"10.1136\/ard-2023-224343_bib27","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","author":"Hellmich","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224343_bib28","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224343_bib29","unstructured":"Harigai M, Narita I, Suda T, et al. ANCA-associated vasculitis clinical practice guideline. In: SHINDAN TO CHIRYO SHA. Tokyo, Japan, 2023."},{"key":"10.1136\/ard-2023-224343_bib30","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/ker205","article-title":"Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K","volume":"50","author":"Fujimoto","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224343_bib31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T17:43:25Z","timestamp":1737222205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724003935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0003496724003935"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224343","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}